Pinto Beans & Penny Stocks 2020 (BEAN)

[Golden Cross]

~$VSEE Many Reasons To Like VSee Here! VSee is the Most Trusted HIPAA Compliant Telemedicine Solution.

[Golden Cross]

$IQST TINY FLOAT Stock Gets a BUY Rating & $18-22 Price Target

[gladeshawk]

CNRC??? NEWS. Just a FYI. At a minimum keep on your watch lists. HAWK

https://finance.yahoo.com/news/cnrc-announces-change-control-management-121500574.html

[Solarman]

Great list of reasons.

[Golden Cross]

$NGCG .0007 Top Trip-000 Play

✅️ New Owner Shell Sold
✅️ 56% Outstanding Shares Restricted
✅️ New Mergers & Acquisitions Division
✅️ Partnerships on the way per CEO
✅️ Trades thin, can move quick
✅️ Ground floor
✅️ Great SS
✅️ Pretty much still undiscovered
✅️ News/updates coming

[3331]

BIEL: HUGE HIT IN SOUTH AFRICA!
https://beprepared365.co.za/products/2/actipatch

[ProfitScout]

$AMOD News: Alpha Modus (NASDAQ: AMOD) CEO Doubles Down with $3M Commitment Amid Execution Milestones and Imminent Revenue Surge

CORNELIUS, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD), a retail AI and data monetization company, today announced a major personal capital commitment from its CEO William Alessi to further support the company’s rapid growth and operational plans for the remainder of 2025.

In a strong display of confidence, Mr. Alessi and his affiliated family trusts have recently completed the exchange of a substantial block of preferred shares into common stock, aligning long-term interests with shareholders. Now, he has personally committed up to $3 million in simple debt financing to ensure Alpha Modus remains well-capitalized and strategically focused through year-end while rejecting all third-party derivative financing offerings.

“This is not just a vote of confidence,” said William Alessi, CEO of Alpha Modus. “It’s a clear signal: we are executing exactly as we said we would, and we’re entering the most transformative revenue period in our company’s history. I believe short interest in our stock is severely miscalculated and based on outdated assumptions tied to de-SPAC stigma and trading algos—not fundamentals.”

Since its de-SPAC listing, Alpha Modus has executed its commercialization roadmap with discipline and precision. The company’s robust pipeline of enterprise contracts—ranging from 7 to 9 figures—is now unfolding across the back half of 2025. Management anticipates reaching positive cash flow by year end based on existing implementation schedules.

Alpha Modus continues to leverage its expansive patent portfolio through successful enforcement and monetization campaigns. The company's strategy to convert former legal adversaries into strategic partners has been validated through deals with VSBLTY and CashX, with several more partnerships under advanced negotiation.

“We don’t pivot. We don’t dilute vision. We execute,” Alessi added. “I believe the market will see that this team, this technology, and this IP portfolio are significantly undervalued. I welcome the shorts to continue their efforts and look forward to a future short squeeze when we prove them wrong—we’re just getting started.”

The company has applied to transfer its securities listing to the NASDAQ Capital Market and believes it will be compliant with all applicable Nasdaq listing standards upon transfer.

Alpha Modus intends to maintain a lean operational model with strategic financial support from its CEO, and it is focused on avoiding all variable rate financing in the future, which financing could compromise the value of its common shares.

For more information and to access Alpha Modus’ press room, visit: https://alphamodus.com/press-room/

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus’s actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus’s expectations with respect to future performance.

Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contact Information

Investor Relations
Alpha Modus Holdings, Inc.
Email: [e-mail]
Website: www.alphamodus.com

Follow us on LinkedIn | Follow us on X

https://www.globenewswire.com/newsroom/ti?nf=OTQ4MjQ4NSM3MDEyNjE4IzIyNjM1NDM=
https://ml.globenewswire.com/media/Y2U1ZmFlNmYtMGVhNy00MGFiLTkwZTgtYTJjODIyYzY5OGZkLTEyNzUwOTMtMjAyNS0wNi0yMy1lbg==/tiny/Alpha-Modus-Corp-.png

Source: Alpha Modus Corp.

[ProfitScout]

$IVDN News: Innovative Designs Delivers Record Sales Growth and Highest Profitability Level to Date for First 6 Months of 2025 With 265% Increase Year-Over-Year
https://www.newmediawire.com/news/innovative-designs-delivers-record-sales-growth-and-highest-profitability-level-to-date-for-first-6-months-of-2025-with-265-increase-year-over-year-7080910

$IVDN News: Innovative Designs Delivers Record Sales Growth and Highest Profitability Level to Date for First 6 Months of 2025 With 265% Increase Year-Over-Yearhttps://t.co/mhEYJuGG45 #Profitability #RevenueGrowth #HomeBuilding #Insulation #Construction #Insultex pic.twitter.com/oTsgcXERGK

— Innovative Designs, Inc (Stock: $IVDN) (@riccelli_joseph) June 17, 2025

[3331]

BIEL: 911 "news pending" market maker trade a little and multiple 100 "I need shares" market maker trades Friday!

[Mrspencers]

$CBLO | C2 BLOCKCHAIN: Cardano (ADA) Acquisition Signals Long-Term Vision

C2 Blockchain Inc. ($CBLO) is in the process of acquiring 1,000,000 ADA — a strategic move aimed at strengthening its position in the blockchain space.

• ADA Focus: Cardano’s energy-efficient architecture and growing DeFi ecosystem align with CBLO’s commitment to scalable, responsible tech.
• Digital Asset Strategy: This acquisition forms the backbone of CBLO’s treasury approach, mirroring institutional tactics seen in early crypto adoption.
• Ecosystem Expansion: Alongside mining and AI fintech development, ADA becomes a key pillar in CBLO’s multi-sector blockchain footprint.
• Transparency & Execution: Publicly reported, actively building — a methodical approach to blockchain operations.

This isn’t hype — it’s a structural commitment to quality assets.

[gladeshawk]

LTUM>>>>Volume up and price moving up. HAWK

[ProfitScout]

$IVDN Feature: 150% Increase in Fiscal Q2 Sales vs Previous Year to $750,000; Continuous Record Quarters & Profitability for Homebuilding Product: Innovative Designs

$IVDN Innovative Designs, Inc. (Stock Symbol: IVDN) Board Member has Ties to Industry Leaders Including D.R. Horton $DHI, Ryan Homes $NVR and More / Super Small Share Structure with Only 38 Million OS / 16 Million Float
LINK:
https://www.prlog.org/13078241-150-increase-in-fiscal-q2-sales-vs-previous-year-to-750000-continuous-record-quarters-profitability-for-homebuilding-product-innovative-designs.html

From the article:

Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating, Water Vapor, Air & Wind Barrier and Other Important Advantages.

Second Quarter Revenue Projection of $750,000 (150% Increase Over Q2 of Previous Year).

First Half of 2025 Already Approximately Equals All of 2024 Revenue Total.

Fiscal First Quarter Results Deliver Over a 720% Increase, Largest Percentage Revenue Growth in Company History.

Profitability Reached for First Time at Fiscal 2024 Year-End on Almost 300% Revenue Increase vs. Previous Year.

New Government Building Codes Require Continuous Insulation with Higher Performance. IVDN Meets or Exceeds These Standards Where Many Competitors Now Do Not.

Increased Order Fulfilment Capabilities with Plans for Further Enhancement to Handle Strongly Increasing Demand.

[Golden Cross]

$LITM Snow Lake is actively pursuing acquisitions in the nuclear energy sector to expand its project pipeline! Bet we hear more news soon... Adding here when I can...

#Uranium #Nuclear #cleanenergy #mining

[Golden Cross]

$LITM U.S. Administration's Nuclear Executive Orders Help Fast Track Snow Lake's Pine Ridge Uranium Project Development Timelines
https://www.newsfilecorp.com/release/253433/U.S.-Administrations-Nuclear-Executive-Orders

[gladeshawk]

LTUM, QS related to new solid state EV battery. FYI. HAWK

https://www.msn.com/en-us/news/technology/startup-embarks-on-quest-to-develop-next-gen-batteries-that-could-revolutionize-electric-vehicles-we-can-be-competitive/ar-AA1Fub49?ocid=msedgntp&pc=DCTS&cvid=f28f063f66894d86b7bc321614cc2d48&ei=34

[3331]

BIEL - RecoveryRx now available to all veterans at all VA's!

[linkvest]

ASII.... You don't own this stock? You should......... https://www.otcmarkets.com/stock/IQST/news/IQST---IQSTEL-Sparks-Rapid-Global-Fintech-Expansion-with-GlobeTopper-Acquisition----Fast-Tracking-1-Billion-Growth-Plan?e&id=3251837

[2times2]

MSRM + Mycolab INC., Market cap ridiculously low, SS tiny and unchanged, Independent directors, Products rolled out, first (small) revenue reported, management certification filed to list on OTCID come July

Authorized Shares 400,000,000 05/27/2025
Outstanding Shares 39,435,760 05/27/2025
Restricted 26,839,148 05/27/2025
Unrestricted 12,596,612 05/27/2025
https://www.otcmarkets.com/stock/MSRM/disclosure

https://www.mushroomsinc.com/
https://mycolabx.com/

[3331]

BIEL - HOT NEW PRODUCT, RAVE REVIEWS!
https://mcintyre-canine-rehabilitation.mykaja...pwaQWVSUHw

[3331]

BIEL + DR OZ = $$$
https://www.facebook.com/ActiPatch/videos/423907841012124/?mibextid=rS40aB7S9Ucbxw6v

[Zardiw]

So I was talking to my friend and good stocks came up.

I told him about $OODH oil/gas co, and how they got zero debt.

He said he'd never heard of that......and I haven't either fwiw:



Z

[Golden Cross]

$OODH Market Cap insanely low here! $10 Million in Rev's last year and growing monthly!

[3331]

BIEL - VA HUGE
Flagship product RecoveryRX now available to all veterans at all VA's!
An American hero gives a fantastic testimonial about Bioelectronics flagship product - RecoveryRX!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980584
Ted Fienning
BioElectronics Corporation
Harvard University
Marine Corp Pilot
"Share with any veteran you know using the VA: RecoveryRX is an FDA-approved pain management device now available nationwide at every VA. Non-opioid, non-invasive, and available by asking your VA provider."

[Zardiw]

$OODH News: More Royalty Assets Acquired!!:

Tom Lull, CEO: "We now have 3-2 ½ mile horizontal wells drilled on our royalty acreage in the Scoop Stack of Oklahoma. We anticipate revenue checks from 2 of these horizontal wells in Kingfisher County Oklahoma will start to pay in late May 2025. We anticipate revenue from the 2 ½ mile horizontal well recently drilled in Grady County Oklahoma will pay in late June 2025. Orion has more than 1,000 royalty acres in the Scoop Stack area surrounding Oklahoma City." Commented Tom Lull, CEO of Orion. Orion's revenues exceeded $20,000 in the month of April 2025 from our royalties and non op working interest outside of Oklahoma. Orion now owns 53,160 mineral acres in the Bakken, Permian Basin, Piceance Basin, Arkoma Basin, Eagle Ford, and Scoop Stack of Oklahoma. "

https://www.accessnewswire.com/newsroom/en/orion-announces-oklahoma-scoop-stack-royalty-acquisitions-1030938

Z

[Golden Cross]

$OODH Undervalued Oil & Gas Play

[ProfitScout]

$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

PALM BEACH, Fla., May 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will be presenting a Company update at the upcoming Wall Street Conference, taking place on May 21, 2025 in Palm Beach, FL. NRx is one of six companies invited to present.

The Wall Street Conference is expected to host over 1,000 attendees who are reported to represent over $1T in investment capital. Wall Street Conference Home

NRx will be discussing recent progress towards FDA approval of NRX-100 (preservative-free ketamine) and upcoming acquisitions of HOPE clinics providing state-of-the-art care for suicidal depression, PTSD, and related disorders.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (preservative free IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including, without limitation, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, NRX-100 not being approved by the United States Food and Drug Administration, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

Matthew Duffy

Brian Korb

Co-CEO, Hope Therapeutics, Inc.

Managing Partner, ASTR Partners

Chief Business Officer, NRx Pharmaceuticals, Inc.

[phone]

[e-mail]

[e-mail]

https://c212.net/c/img/favicon.png?sn=CL91815&sd=2025-05-21 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-selected-to-present-at-the-wall-street-conference-on-may-21-2025-in-palm-beach-florida-302461059.html

SOURCE NRx Pharmaceuticals, Inc.

[3331]

BIEL's RecoveryRx HUGE in plastic surgery.
Steven Ray Garcia Owner/Operator-Sandlot Medical: "This is a great product. I work with a couple top Plastic Surgeons in Scottsdale, and Recovery RX is part of their breast augmentation recovery protocol."

[Golden Cross]

$NGCG .0011 Easy Multi-Bagger From Here!

[toastturtle]

$ISPNF Low Float Gold Play. New US and German Listings. Only 18M shares out. Just announced German Marketing Group Plutus who have good results form many companies in the JR market. Drill program expected in roughly 6 weeks. Airborne surveys being completed now. Trading below $0.15 currently but shouldn't be there long. Feel like it could double by the time the work starts. Not a recommendation. Do some DD.

[3331]

BIEL: 5 STARS!
Green Light ON...Pain is Gone!
Reviewed in the United States on May 5, 2025
I've been using this for a few years now and works great on my lower back and knee pain. I put one on my lower back before golf each week and zero pain. Highly recommend and don't leave home without it.

[Mermelstein]

INBP - $0.33. 2 cent EPS reported. Added some more today in the low .30s. Can't really find anything I like better than this at the moment.
~$10m market cap
$3m in net cash
$50m+ revenue
$0.02 EPS last Q, fully taxed
Around 3x ttm EV/EBITDA
Tangible Book value 100% higher
Billionaire owners of Celsius energy drinks own almost 50% of the stock. Think they will just buy out the other half of the company eventually.

[ProfitScout]

$CVKD: Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

PONTE VEDRA, Fla.--(BUSINESS WIRE)-- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy.

Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently underway.

“We are pleased with the important progress we have made with the supply chain and cGMP manufacturing process for tecafarin,” said Quang X. Pham, Chairman & CEO. “This is a key milestone as we support our clinical development strategy and tecarfarin’s potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation.”

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for several indications, extensive clinical and real-world data have shown it can have significant, serious side effects.

Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).

Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit https://www.cadrenal.com/ and connect with us on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding tecarfarin’s potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation and pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation, the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20250515408603r1&sid=acqr8&distro=nx&lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515408603/en/

Corporate and Investor Relations
Paul Sagan
LaVoieHealthScience
[phone]
[e-mail]

Media
Andrew Korda
LaVoieHealthScience
[phone]
[e-mail]

Source: Cadrenal Therapeutics, Inc.

[BGCapital]

ADHC share holder update on X today

$ADHC Shareholder update out just now!

They have a lot going on right now. Keep an eye out for PRs

Also they received a favorable review by the FDA on their Breakthrough Device application a few weeks ago. Glucoguard coming closer to breakthrough device designation by the FDA… https://t.co/X8uoaU44LW

— Stock Picks NYC (@StockPicksNYC) May 14, 2025

Keep an eye out for multiple PRs on the way

[BGCapital]

ADHC share holder update on X today

$ADHC Shareholder update out just now!

They have a lot going on right now. Keep an eye out for PRs

Also they received a favorable review by the FDA on their Breakthrough Device application a few weeks ago. Glucoguard coming closer to breakthrough device designation by the FDA… https://t.co/X8uoaU44LW

— Stock Picks NYC (@StockPicksNYC) May 14, 2025

Keep an eye out for multiple PRs on the way

[Golden Cross]

$NGCG brand new 000 play here!

[3331]

BIEL: HUGE HIT IN SOUTH AFRICA!
https://beprepared365.co.za/products/2/actipatch

[Golden Cross]

$LITM Snow Lake’s strategic focus on uranium — a critical resource in the clean energy transition.
https://allcapresearch.com/f/snow-lake-energy-litm-expands-global-uranium-push

[3331]

BIEL - VA HUGE, ÷200%
https://veteranrecovery.org/
Flagship product RecoveryRX now available to all veterans at all VA's!
Ted Fienning
BioElectronics Corporation
Harvard University
Marine Corp Pilot
"Share with any veteran you know using the VA: RecoveryRX is an FDA-approved pain management device now available nationwide at every VA. Non-opioid, non-invasive, and available by asking your VA provider."
An American hero gives a fantastic testimonial about Bioelectronics flagship product - RecoveryRX!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980584

[Golden Cross]

$NGCG New 000 Play! Shell Sold_New Owner_Very Early Here!

[TheFinalCD]

https://www.youtube.com/shorts/yJ2LOVU-23Q

🙏✝️ for you and your family, and what a Blessing to see your daughter

my mother in law is battling stage 4 cancer😕

Cancer is an incredible force

but not an unbeatable one

Peace & Cheese brotherrrrr

[TheFinalCD]

https://www.youtube.com/shorts/yJ2LOVU-23Q

[gladeshawk]

LTUM >>> Recent increase in volume and pps. This could be the reason. Lithium prices to see increases soon. Just a FYI. HAWK

https://finance.yahoo.com/news/lithium-corporation-commences-2025-field-102000340.html

[Golden Cross]

$LITM Looking for a nice Post-RS move! $20 Million Cash on hand! Think we can see a 50-100% move soon!

Could hear news out of the Critical Minerals Conference today! Loading up... Trading at about cash value here!

[gladeshawk]

LTUM>>>> Pure penny play. Executive Order from WH put out to help in increase U.S. rare earths production. Bigger move UP is coming, imho. At a minimum keep on your watch lists. Just a FYI. HAWK

[3331]

BIEL - Actipatch/Recovery Wave huge in the UK, covered by the National Health Service (NHS)!

NEW ZEALAND SALES LAUNCHED!
https://www.actipatch.nz/

[TheFinalCD]

https://www.youtube.com/shorts/BDwjToHoOLo

[linkvest]

RDAR... NEWS NEWS NEWS Telvantis, Releases the Interview From the Floor of the NYSE on YouTube https://finance.yahoo.com/news/raadr-inc-doing-business-telvantis-123000456.html

[linkvest]

RDAR... RDAR should be in your portfolio today..... The NYSE floor interview date is set for April 23, 2025. The release of the interview to the public will be on April 30, 2025.
The selection of topics will include the following:
Acquisitions and corporate expansion plans
PCAOB audit updates
Revenues
“Both shareholders and the Company have gone through some amazing transformations over the past few months as we completed Phase 1 and moved on to Phase 2 of our 2025 growth strategy. To be selected for an interview on the floor of the NYSE is an honor and testament to what we are building here at Telvantis,” commented Daniel Gilcher, CFO of Telvantis, who will be representing the Company on the floor of the NYSE.

[BGCapital]

ADHC woah!! Received favorable FDA review see today news

$ADHC pretty big news today! Received Favorable FDA Review

“Virtually all of the requirements for Breakthrough Designation were acknowledged by the FDA to have been fulfilled in the GlucoGuard® application

Specifically, the FDA acknowledged that:

•The GlucoGuard® device… https://t.co/nwTCymEmXL pic.twitter.com/EJddxT0ccr

— Stock Picks NYC (@StockPicksNYC) April 29, 2025

The market cap is only $1M so it can actually run up pretty high from here

[Magnum7419]

$AHRO :)